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Multiple sclerosis (MS) is regarded as a disease with a multifactorial
aetiology, comprising genetic as well as environmental inﬂuence.
Migration studies, geographical gradients and high rates of discordance
in identical twins point to the inﬂuence of environmental factors inter-
acting with genetics in determining disease susceptibility [1]. The land-
mark work of Kurtzke [2] showed that the MS risk declined twofold
withmigration from high- to low-risk areas which indicate that genetic
factors can account for only a small proportion of geographical MS
variety. This was also supported by others [3], suggesting a role for a
range of physical, chemical, biological and social environmental factors.
Moreover, the evidence on the rising worldwide prevalence and
increasing female to male ratio focuses the interest on environmental
factors [4].
The environmental risk factors implicated include sun exposure,
vitamin D status, Epstein–Barr virus (EBV) infections and smoking.
These factors combined can interact at different time points prior to
and following the clinical onset of MS [5]. Cigarette smoking is emerg-
ing as one of the most postulated environmental risk factors linked to
onset and clinical course of MS in genetically susceptible individuals
[6,7]. The history of the suggested association between MS and smok-
ing goes back to the 1960s when few studies were performed,
although these studies did not reach signiﬁcance and analysed a
large number of variables simultaneously [8,9].
In this reviewwe aim to give an overview of the studies conducted
on the association between smoking and MS susceptibility, andclinical course. In addition, we discuss the possible pathogenic role
of smoking in MS and the related underlying mechanisms. Finally,
we provide some arguments supporting, but also some challenging
this association.
2. Cigarette smoking and risk of MS
Several retrospective and prospective studies have investigated
the association between smoking and MS susceptibility. Table 1
gives a chronological summary of the key studies. One of the earliest
papers to include smoking habit was an exploratory case–control
study from Israel in 1965 [8], where 241 MS patients were questioned
about ever smoking prior to disease onset. The control group included
964 subjects individually matched to patients by age, sex and region
of birth. They found signiﬁcantly more previous smokers in the
patient group (44% vs. 36%, p=0.02). However, they did not correct
for multiple comparisons.
It was not until the 1990s that two longitudinal studies among
women in the United Kingdom [10,11] showed that women who reg-
ularly smoked were found to have a higher risk of MS, although these
ﬁndings were not signiﬁcant. In the Oxford Family Planning Associa-
tion Study, the incidence of MS in women who smoked ≥15 ciga-
rettes per day was 1.8 (95% CI 0.8–3.6) times higher than in women
who never smoked [10]. The Royal College of General Practitioners'
Oral Contraception Study demonstrated comparable ﬁndings with
the incidence of MS in women who smoked ≥15 cigarettes per day
1.4 (95% CI 0.9–2.2) times higher than never-smokers [11]. It should
be noticed that both studies included only females and small number
of incident cases of MS (63 and 114 respectively). Furthermore, asses-
sing smoking history was a secondary question since both studies
were conducted to investigate the possible relation of oral contracep-
tives and MS risk.
Table 1
Chronological summary of fourteen main studies examining cigarette smoking and MS onset.
First author
Publication year
Number of cases Number of controlsa Female/male ratio Quantity smoked
(Number of cases)b
OR/ RR (95% CI) Adjustments
and/or matching
Study type and comment (Country)
Antonovsky et al. [8] 241 964 0.8 Ever-smoker (106) OR 1.4 (1.1–1.9) Age, sex, region of birth Case–control study. (Israel)
Villard-Mackintosh
and Vessey [10]
63 17,032 All females Ex-smoker (9) RR 1.5 (0.6–3.3) Age, parity, clinic,
date of admission to study
Prospective cohort study. (UK)
Current smoker (26)
1–14/day (14) RR 1.6 (0.8–3.1)
≥15/day (12) RR 1.8 (0.8–3.6)
Thorogood and
Hannaford [11]
114 46,000 All females Ever-smoker (58) Age, parity, social class Prospective cohort study.
Incident cases. All smokers
started before disease onset. (UK)
1–14/day (33) RR 1.2 (0.8–1.8)
≥15/day (25) RR 1.4 (0.9–2.2)
Ghadirian et al. [15] 200 202 2.2 Ever-smoker (138) OR 1.6 (1.0–2.4) Age, sex, education Incident case–control.
Smoking in year prior to
diagnosis. (Canada)
0–b10/day (15) OR 0.7 (0.3–1.5)
10–20/day (34) OR 1.4 (0.8–2.4)
20–40/day (71) OR 1.9 (1.2–3.2)
≥/40/day (16) OR 5.5 (1.7–17.8)
Hernan et al. [12] 315 237,264 All females Ex-smoker (79) RR 1.2 (0.9–1.6) Age, latitude, ancestry. Prospective study in NHS
and NHS IIc cohorts. Smoking
4 years prior to MS diagnosis. (USA)
Current smoker (96) RR 1.6 (1.2–2.1)
Ever-smokers (175)
1–9 pack years (43) RR 1.1 (0.8–1.6)
10–24 pack years (75) RR 1.5 (1.2–2.1)
N25 pack years (57) RR 1.7 (1.2–2.4)
Riise et al. [21] 86 22,312 NR Ever-smoker (65) RR 1.8 (1.1–2.9) Age, sex Population based
cross-sectional study. (Norway)Female (NR) RR 1.6 (ns)
Male (NR) RR 2.8 (ns)
Zorzon et al. [16] 140 131 1.8 Ever-smoker (79) OR 1.5 (0.9–2.4) Age, sex Case–control study. (Italy)
Current smoker (58) OR 1.9 (1.1–3.2)
Hernan et al. [13] 201 1913 2.4 Ex-smoker (NR) OR 1.0 (0.6–1.8) Age, sex, family practise,
date of joining practise and
availability of smoking
information
Prospective, nested
case–control study. (USA)Current smoker (NR) OR 1.4 (1.0–1.9)
Ever-smoker (92) OR 1.3 (1.0–1.7)
(continued on next page)
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Table 1 (continued)
First author
Publication year
Number of cases Number of controlsa Female/male ratio Quantity smoked
(Number of cases)b
OR/ RR (95% CI) Adjustments
and/or matching
Study type and comment (Country)
Pekmezovic et al. [17] 196 210 2.8 Ever-smoker (114) OR 1.6 (p=0.02) Age, sex, residence Case–control study. (Serbia)
≤15/day (67) OR 1.5
≥16/day (47) OR 1.7
(p-trend=0.02)
Hedström et al. [22] 902 1855 2.6 Ex-smoker (195) OR 1.4 (1.1–1.8) Age, sex, ancestry, residence Population based
case–control study. (Sweden)Current smoker (322) OR 1.6 (1.3–1.9)
Ever-smoker (517) OR 1.5 (1.3–1.8)
Female (362) OR 1.4 (1.2–1.7)
Male (155) OR 1.8 (1.3–2.5)
Rodriguez Regal et al. [18] 138 138 2.1 Ex-smoker (21) OR 3.3 (1.4–7.8) Age, sex, residency Case–control study. (Spain)
Current smoker (66) OR 2.0 (1.2–3.3)
Ever-smoker (87) OR 2.2 (1.3–3.6)
Female (NR) OR 2.6 (NR)
Male (NR) OR 1.3 (NR)
Jafari et al. [24] 136 204 1.7 Ex-smoker (21) OR 1.2 (0.7–2.2) Age, sex Case–control study in
multiplex families.
(The Netherlands)
Current smoker (43) OR 1.0 (0.6–1.7)
Ever-smoker (64) OR 1.1 (0.7–1.7)
b7.9 pack years (32) OR 1.0 (0.6–1.8)
≥7.9 pack years (32) OR 1.2 (0.7–2.1)
Da Silva et al. [19] 81 81 2.1 Current smokerd (28) OR 2.0 (0.9–4.3) Controls paired for sex,
age, place of birth
Case–control study. (Brazil)
Carlens et al. [14] 214 277,777 All males Ever-smoker (150) RR 1.9 (1.4–2.6) Age, region of residence,
Swedish moist snuff
Prospective cohort study. (Sweden)
Simon et al. [20] 441 865 4.2 Ever-smoker (264) OR 1.4 (1.1–1.8) Age, sex Case–control study including
NHS and NHS IIc (USA), Tasmanian
(Tasmania) and Swedish
MS study (Sweden)
Odds ratio (OR), rate ratio (RR), conﬁdence interval (CI), not reported (NR).
a For cohorts total number followed up are given.
b Reference category classiﬁed as never-smoker.
c NHS = Nurses' Health Study (1976–1994) and Nurses' Health Study II (1989–1995).
d Reference category classiﬁed as never-smoker and ex-smoker.
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formed, which comprised more than 200,000 women participating
in the Nurses' Health Study and Nurses' Health Study II and included
315 MS cases. This study showed a signiﬁcant increase in MS risk
among current smokers (OR 1.6, 95% CI 1.2–2.1). They also showed
that the incidence of MS increased with the cumulative exposure to
smoking [12]. The outcome was adjusted for age, latitude and ances-
try. To be noted, they studied smoking behaviour 4 years prior to MS
diagnosis. Next, the same study group investigated the association
between MS and smoking in a nested case–control study based on
the General Practice Research Database including 201 cases. They
conﬁrmed the higher MS risk for ever-smokers and current smokers
(respectively OR 1.3, 95% CI 1.0–1.7 and OR 1.4, 95% CI 1.0–1.9) com-
pared to never-smokers [13]. Another prospective study was pre-
sented by Carlens and colleagues [14], who showed in a large
cohort with 214 incident cases that the relative risk associated with
ever-smoking was 1.9 (95% CI 1.4–2.6). Interestingly, this cohort in-
cluded only males.
These results are consistent with several retrospective case–
control studies [15–20], and population based surveys [21,22]
(Table 1). Ghadirian et al. [15] showed in a case–control study of
200 incident MS cases from Montreal that ever-smoking was signiﬁ-
cantly associated with a higher MS risk (OR 1.6, 95% CI 1.0–2.4) and
concurred with the stronger association for heavy smokers. Their
analysis was based on reported cigarette smoking in the year prior
to MS diagnosis and was adjusted for age, sex and education.
In a survey of the general population of Hordaland, Norway, in-
cluding 22,312 individuals of which 86 had MS [21], the risk of inci-
dent MS among current and ex-smokers was 1.8 (95% CI 1.1–2.9)
times higher than the risk in subjects who had never smoked. Males
had a higher risk ratio (RR 2.8) compared to females (RR 1.6), 95%
CI were not given. The sex difference has also been demonstrated
in a population based case–control study in Sweden. Hedström and
colleagues [22] showed a higher OR for males compared to females
(OR 1.8 vs. 1.4), next to a signiﬁcant higher risk of MS for ever-
smokers (OR 1.5, 95% CI 1.3–1.8). In 2009 Rodriguez Regal et al.
conﬁrmed in a Spanish case–control study the association of cigarette
smoking and MS. Surprisingly, in contrast to other studies they
showed stronger effect among ex-smokers (OR 3.3, 95% CI 1.4–7.8)
compared to current smokers (OR 2.0, 95% CI 1.2–3.3).
There are few studies, which did not show an association between
MS and smoking. Some of these studies were subject to methodolog-
ical limitations. Casetta et al. [23] performed a community-based
case–control study in Ferrara, Italy. The MS population including
104 subjects was compared to 150 controls. Their study demonstrated
no association between MS risk and smoking (results not shown). It is
to be noted that they collected data on smoking and drinking in adoles-
cence. In a recent case–control study inmultiplex families [24], wewere
not able to show an association of smoking and MS. This was possibly
due to the higher genetic susceptibility in the multiplex families,
which could obfuscate the role of smoking.
Recently it was demonstrated that exposure to environmental
tobacco smoke is associated with an increased risk of MS. A French
case–control study showed a positive association between parental
smoking at home and early onset MS in their children [25], suggesting
a role for passive smoking. However, another study demonstrated no
effect of maternal smoking during pregnancy on early onset MS in off-
spring [26]. Hedström and colleagues observed that never-smokers,
who reported that they had been exposed to passive smoking, had
an increased risk of developing MS compared to those who reported
never to have been exposed (OR 1.3, 95% CI 1.1–1.5). The risk
increased signiﬁcantly with longer duration of exposure [27].
Complementary to the studies investigating the association
between cigarette smoking and MS susceptibility, a group in Austria
studied the role of smoking after a ﬁrst demyelinating event [28].
The clinically isolated syndrome (CIS) is the most common andrecognised onset of MS. Most of the CIS patients with disseminated
white-matter lesions on brain magnetic resonance imaging, and/or
positive oligoclonal bands in the cerebrospinal ﬂuid will develop clin-
ically deﬁnite MS (CDMS) after a second relapse [29]. Di Pauli and col-
leagues [28] suggested that cigarette smoking was a risk factor for
early conversion. They observed that a patient who smoked at onset
of MS had a 1.8 fold increased risk of conversion to CDMS over
3 years compared with non-smokers (p=0.008). It should be noted
that there was a higher proportion of smokers in their CIS patients
(46%) relative to the general population of Austria (29%), however
this reference group was not age and sex matched.3. Cigarette smoking and the clinical course of MS
Aggravation of MS symptoms shortly after starting to smoke has
been reported in several early studies [9,30–32]. The relationship
between smoking and disease progression is still arguable. Some
studies have suggested increased risk and others showed no effect.
The variability in outcome of these studies can partly be explained
by different measurements used for progression. Some studies inves-
tigated symptom aggravation or relapse rate; others used Kurtzke
Expanded Disability Status Scale (EDSS) or MS Severity Scales
(MSSS) to study disease disability in MS, but most of the studies
focused on conversion to secondary progressive MS (SPMS).
An acute worsening of MS symptoms immediately following
smoking was reported in a few clinical studies conducted more than
40 years ago [9] and it was conﬁrmed in later investigations [32].
Emre and De Decker [32] showed that cigarette smoking causes a
transient worsening of motor functioning. They used a battery of
tests in 21 MS patients compared to healthy controls. In a prospective
cohort study including 142 relapsing remitting MS (RRMS) patients,
Pittas and colleagues showed no statistically signiﬁcant associations
between relapse rate and smoking behaviour. The hazard ratio (HR)
for ever-smokers was 0.9 (95% CI 0.7–1.3) and for current smokers
1.0 (95% CI 0.6–1.6) [33]. There was also no dose related association.
These analyses were adjusted for entry MSSS, follow-up time, gender,
age at entry review, immunomodulatory treatment use, education
level and month of review.
Interestingly, they demonstrated in the same study that increasing
smoking pack years were positively associated with progression of
clinical disability within the observation period, depicted in the
MSSS and EDSS (pb0.001). These effects persisted after further
adjustment for factors like, time outside or in the sun in previous
6 months, serum 25(OH)D, total alcohol and ﬁsh intake [33]. A Swedish
study estimated the effects of smoking in MS also using self-reported
data on smoking habits in 122 incident cases. They assessed the MS
disability using EDSS after a median disease duration of 6 years and
showed that progressive disease disability was signiﬁcantly more likely
to occur in ever-smokers when compared with never-smokers
(p=0.006). Individuals with an early smoking start (≤15 years of
age) scored higher compared with those starting smoking later
(N15 years of age) (p=0.005) or never-smokers (pb0.001) [34]. Also
themeasurements byMSSS showed that ever-smokers have in average
a signiﬁcantly higher disability than never-smokers (median MSSS 5.2
versus 3.2, p=0.042) [34]. And ever-smokers with early debut had in
average a signiﬁcantly higher disability than late starting smokers or
never-smokers (median MSSS 6.5, 4.6 and 3.2; p=0.011 and
p=0.002, respectively). However, another study assessing the impact
of smoking on disability could not conﬁrm these ﬁndings [35]. They
compared prospectively collected clinical information with retrospec-
tively collected data on smoking and reported that smoking was not
related to time to reach the disability milestones of EDSS 4.0 or 6.0.
Age at disease onset was the only variable associated with a shorter
time to both EDSS milestones (pb0.001). Though, they demonstrated
that pack-years smoked after the onset of MS were signiﬁcantly
Table 2
Studies on the association between cigarette smoking and secondary progression of MS.
First author
Publication year
Number of
RRMS cases
Female/male
ratio
Quantity smoked
(MS number)
Regression analyses
HR (95% CI)a
Adjustments
and/or matched
Study type and
comment (Country)
Hernan et al. [13] 179 2.4b Ever-smoker (81) 3.6 (1.3–9.9) Age, sex, motor clinical onset Prospective cohort study. (UK)
Koch et al. [35] 271 2.4 Ever-smoker (192) 0.9 (0.6–1.3) Age at disease onset, sex. Prospective cohort study
with retrospective smoking
data collection. (The Netherlands)
Sundström and
Nystrom[34]
96 2.1 Ever-smoker (56) 2.4 (1.0–6.0) Age at disease onset, sex Retrospective cohort study.
(Sweden)
Pittas et al. [33] 148 2.2b Total pack years smoked
at cohort entry
OR 1.0 (1.0–1.1) Age at cohort entry, sex,
disease duration,
Prospective cohort study.
(Tasmania)
Healy et al. [36] 891 3.0b Current smoker (154) 2.5 (1.4–4.4) Age, sex, disease duration
from symptom onset.
Prospective cohort study. (USA)
Ex-smoker (237) 1.1 (0.6–1.8)
Hazard ratio (HR); adjusted odds ratio (AOR); conﬁdence interval (CI); relapsing remitting MS (RRMS), not reported (NR).
a Cox Proportional Hazard Regression was performed by the studies.
b Female/male ratio shown for the total cohort in the study, not limited to RRMS.
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p=0.03) and in women (rho=−0.15, p=0.02).
In 2009 Healy and colleagues did also not found any association
between smoking status and EDSS progression at the end of 2 and
5 years [36]. The percentage in whom disease progressed after
2 years was 23.3% in ever-smokers, 30.8% in ex-smokers, and 26.0%
in never-smokers (p=0.57, adjusted for baseline age, sex, disease
duration, and treatment). They also studied progression in terms of
brain MRI changes. They showed a signiﬁcantly greater increase in
T2-weighted lesion volume in current smokers compared with
never-smokers (p=0.02, adjusted for baseline age, sex, disease dura-
tion and disease course). In 2009 Zivadinov et al. [37] conﬁrmed the
association with MS clinical course, measuring disease progression
by EDSS increase but also by MRI lesion volume and atrophy. They
showed that ever-smokers had higher EDSS scores compared to
never-smokers (median EDSS scores 3.0 and 2.5 respectively,
p≤0.001). They also demonstrated that mean number of contrast
enhanced lesions on MRI for ever-smokers was signiﬁcantly higher
compared to never-smokers (mean 1.2 vs. 0.72 respectively,
pb0.001). Moreover, they showed that smoking was associated
with increased lesion burden and greater atrophy (pb0.001).
The major focus of studies investigating association between ciga-
rette smoking and MS clinical course has been on the conversion to
SPMS (Table 2). In 2005 a prospective cohort study using data from
the General Practice Research Database showed that RRMS patients
who smoked had N3 times higher risk of progression to SPMS [13].
This was studied in a small sample of 179 RRMS cases of which only
20 converted to SPMS during a mean follow-up time of 5.3 years.
There were no data on duration or intensity of smoking [13].
Sundström and Nyström showed in 96 RRMS patients that the
increased risk for secondary progression for ever-smokers compared
with never-smokers is not due to differences in sex or age at disease
onset (HR 2.4, 95% CI 1.0–6.0). The hazard ratio was borderline signif-
icant probably caused by the small numbers [34]. Also in another
study was smoking associated with an increased risk of converting
to a secondary progressive course within the cohort follow-up period,
but this ﬁnding appeared partly due to smokers being of older age
with longer disease durations [33]. In 2009 Healy and colleagues
demonstrated in a much larger group of 891 patients an adverse
inﬂuence of cigarette smoking for conversion of RRMS to SPMS [36].
During a mean (SD) follow-up of 3.3 (1.7) years, conversion to
SPMS occurred in 72 patients. Current smokers converted faster
from RRMS to SPMS compared to never-smokers (HR 2.5, 95% CI
1.4–4.4). This was not shown for ex-smokers (HR 1.1, 95% CI 0.6–
1.8). Unlike previous mentioned positive studies, in 2007 Koch and
his group found no association between cigarette smoking and pro-
gression to SPMS [35]. They compared prospectively collected clinicalinformation with retrospectively collected data on smoking. The col-
lection of data on smoking almost 20 years after recruitment of the
patients could be a possible bias.
Taking all these studies into consideration, it is reasonable to con-
clude that smoking is a signiﬁcant, but not powerful risk factor for MS
onset and clinical course. A recently updated meta-analysis showed
that smoking is associated with MS susceptibility in a conservative
model with an RR of 1.5 (95% CI 1.4–1.6). However, the effect of
smoking behaviour on the secondary progression of MS is less certain
(RR 1.9, 95% CI 1.0–3.6) [38].4. Cigarette smoking and biological pathways
As discussed previously, various studies have been performed in-
vestigating cigarette smoke and MS; however, they only indicated
an association. There is no evidence for a possible causal link between
cigarette smoke and MS onset or clinical course. Nevertheless, if we
assume that there is a possible link, then there are several hypotheses
to be considered.
Cigarette smoke contains over 4500 of potentially toxic compo-
nents, including tars, nicotine, carbon monoxide and other particles
[39,40]. Some components of cigarette smoke may have direct toxic
effects on the central nervous system. Cigarette smoke exists of two
phases: a particulate phase and a gaseous phase, both containing
extremely high concentrations of free radicals [40], which may
cause axonal degeneration. The association between smoking and
the risk of MS might be explained by the vulnerability of oligoden-
droglia, compared with astrocytes and microglia, to nitric oxide
[41,42]. Serum concentrations of cyanide, a component of cigarette
smoke, and its main metabolite thiocyanate has long been known to
cause demyelination in the CNS of animals [43]. As discussed earlier,
smoking is suggested to be associated with MS clinical course.
Progressive disease is characterised by the permanent neurological
deﬁcit, which is a result of axonal loss [44]. Exposure to nitric oxide
has been shown to cause axonal degeneration or to block axonal con-
duction, especially in demyelinated axons [45], suggesting a role for
nitric oxide in secondary progressive MS.
Moreover, studies suggesting increased risk for developing MS
[25,27] support a direct role of tobacco components in the pathway.
Interestingly, a recent study in Sweden showed that tobacco
smoking, but not the Swedish snuff, is associated with elevated risk
for MS [22]. This suggests that the critical effects of smoking may be
caused by irritation in the lungs or by increased incidence of respira-
tory infections leading to higher MS risk, which has already been sug-
gested [46]. This pro-inﬂammatory effect of smoking is most likely
triggered via toll-like receptors [47,48].
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in relation to the risk of cardiovascular disease and emphysema [49].
Cigarette smoke stimulates the inﬂux and activation of neutrophils,
monocytes and macrophages [50]. Both current and past smokers
have higher ﬁbrinogen levels, as a marker of inﬂammation, than non-
smokers, and these levels correlate with the number of cigarettes
smoked per day [51,52]. Cigarette smoke elevates peripheral blood
leukocyte counts, [53,54], and is associated with important markers of
inﬂammation like the C-reactive protein and IL-6 [55,56]. Abnormalities
in T-cell function [57,58], reduction in natural killer cells [59] and
impairment of both humoral and cell-mediated immunity [59,60]
have been observed in smokers.
Several hypotheses based on biological mechanisms link cigarette
smoking to MS and to other autoimmune diseases such as rheuma-
toid arthritis [61,62], systemic lupus erythematosus [63], Graves' dis-
ease [61,64] and inﬂammatory bowel disease [65]. This suggests
either an immunomodulation or a pro-inﬂammatory inﬂuence on
the immune system, including an increased pro-inﬂammatory cell
activation in the lungs [66] or post-translational modiﬁcations of
proteins which may break self-tolerance [67], resulting in hypothetical
autoimmune responses against antigens of the nervous system.
Another hypothesis could involve a direct effect of smoke compo-
nents on microvascular blood ﬂow and on the blood–brain barrier.
Nicotine, a major component of cigarettes, has been shown to affect
the integrity and function of the blood–brain barrier (BBB) [68].
This is important because leakage of BBB has been suggested as a fac-
tor in initiating the development of MS. This may be relevant to the
recent report that cigarette smoking increases the risk of converting
from CIS to CDMS [28].
Additionally, cigarette smoking has anti-estrogenic effects as a
result of producing inactive 2-hydroxy catechol estrogens [69,70].
Women who are smokers undergo menopause earlier than non-
smokers [71]. Estrogens can affect the Th1/Th2 immune balance and
also have either pro- or anti-inﬂammatory actions depending on
their concentration [72].5. Discussion
The picture of how environmental exposures lead to autoimmune
diseases in genetically predisposed individuals is becoming more
comprehensive because of the numerous studies in different ﬁelds.
We have discussed different studies investigating the association of
smoking on MS onset and on MS clinical course. A recent meta-
analysis demonstrated that cigarette smoking is important in determin-
ingMS susceptibility but the effect on disease progression is less certain
[38].
There are several limitations to be noted in these studies varying
from recall, response rate, difference between responders and non-
responders, and possible misclassiﬁcation in self-reported data. One
of the most concerning disadvantages of all retrospective and
questionnaire-based studies is that there is a possible recall bias.
However, a recent study showed that participants reliably report
smoking status over time [73]. But even when smoking habit is
explored before MS onset, patients regularly confuse the time of MS
onset with the time of diagnosis. This is sometimes difﬁcult to deter-
mine even for the physicians. As a result, some outcome may relate to
smoking after onset of MS. This issue is prevented in the prospective
studies with data collection, in some studies at least 4 years prior to
the ﬁrst symptoms [12,13]. Another potential methodological prob-
lem in case–control studies is the possible selection bias due to
recruitment. Introducing prospective studies enables measuring ciga-
rette smoke exposure more accurately without recall or report bias.
Preferably, population based studies should be used. However, these
surveys are expensive and collecting a statistically useful group size
of incident cases is time consuming.The heterogeneity in study design and outcome measures makes it
difﬁcult to combine the study results. The time of measurement
differed in the studies; some studies examined the current smoking be-
haviour as a reﬂection of smoking prior to disease onset. There is evi-
dence that smoking behaviour does not change signiﬁcantly after
diagnosis [20], which implies that perhaps the difference in timing is
not of special concern. Different studies showed a higher MS incidence
with the cumulative exposure to smoking, however only few studies in-
cluded the duration and quantity of smoking. It should also be noticed
that the deﬁnition of the ever-smoker group is disputable. The compo-
sition of cigarettes over the years has changed and the quantities of in-
haled toxins in low-tar and ﬁltered cigarettes are unknown.Most of the
studies focused on smoking did not consider passive exposure to tobac-
co smoke, which recently has been linked toMS [27]. Moreover, this ex-
posure may vary considerably by geographic location given the local
smoking laws. In addition, studying MS clinical course the different
studies use a variety of parameters for assessment of MS progression,
such as relapse rate [33], EDSS orMSSS increase [35] and secondary pro-
gression [13,34,36]. These variations in measurements could account
for some of the variability noted in the results.
Cigarette smoking cannot fully explain the latitude gradient of MS,
the changes in risk with migration or the global variation in preva-
lence and sex differences [74]. However, it may partly explain the
recently demonstrated increased female/male ratio in MS incidence
[4,75]. Moreover, investigating the association between smoking
and MS can also be complicated by known and unknown con-
founders. There has been little attention for other health behaviours
such as alcohol intake, body mass index or physical activity, although
it has been suggested that MS patients are risk takers [76,77]. These
factors can inﬂuence the association between smoking cigarettes
and MS. A well-known environmental risk factor for MS is infectious
mononucleosis and the related anti-EBV antibodies. A recent study
in healthy individuals showed that female gender, HLA-DR2 and
cigarette smoking are each positively associated with EBV antibody
levels [78]. This raises questions on the role of EBV in a possible com-
mon pathway associated with these factors [79–81]. Simon and col-
leagues examined the if the effect of smoking is independent from
that of anti-EBNA titres, by comparing the association between
ever-smoking and MS risk with and without adjustment for EBV-
titres [20]. They demonstrated that the increased MS risk associated
with ever smoking (OR 1.4, 95% CI 1.1–1.8) was no longer evident
upon adjustment for anti-EBNA antibody titres (OR 1.1; 95% CI 0.8–
1.4). In cases that had high anti-EBNA titres the risk of MS associated
with ever smoking was increased (OR 1.7, 95% CI 1.1–2.6). Interest-
ingly, the association between increasing anti-EBNA antibody titres
and increased MS risk appeared to be approximately twofold greater
among ever smokers compared to never smokers (OR 3.9, 95% CI 2.7–
5.7 vs. OR 1.8, 95% CI 1.4–2.3), suggesting interaction between smok-
ing and anti-EBNA titres (p for interaction=0.001). They also showed
that the increased risk of MS associated with smokingwas independent
of HLA-DR15 status, although there were implications of between-
study differences. Another study [82] investigating the interaction of
smoking and two human leukocyte antigens (HLA-DR15 and HLA-
A02) associated with MS, showed that smoking increased the MS risk
by a factor of 2.8 in cases with both genetic risk factors in comparison
with a factor of 1.4 in those without both genetic risk factors.
Next to EBV, vitamin D and exposure to sunlight are also important
environmental risk factors associated with MS onset and perhaps even
clinical course [83–86]. More than 30 years ago, vitamin D deﬁciency
was ﬁrst proposed as a risk factor for MS. After discovery of the immuno-
modulatory effects of vitamin D [87,88], a role in MS susceptibility was
warranted. Interestingly, lower serum levels of vitamin D and dietary
intake of vitamin D in smokers have been reported in earlier studies
[89]. An interaction between smoking and vitamin D has been suggested
for rheumatoid arthritis [90], however to our best knowledge this has not
been demonstrated for MS [86].
84 N. Jafari, R.Q. Hintzen / Journal of the Neurological Sciences 311 (2011) 78–85There is no lack of candidate mechanisms by which smoking could
exert effects on susceptibility to MS as well as on the further clinical
course. Different components of tobacco smoke have been discussed
here. The suggestion that components of smoke play a role is also
supported by a recent ﬁnding that even passive smoke exposure
increases the MS risk [27]. Next to nitric oxide, which has putative
roles in demyelination and axonal loss [42,91], some animal studies
have suggested that smoke exposure affects several parts of the
immune system, including innate immunity, B- and T-lymphocytes
and natural killer cells [92,93]. Other possible mechanisms have
been suggested such as smoke induced (local) immunosuppression,
with an associated increase in upper respiratory tract infections [94].
In conclusion, the growing epidemiological evidence for an associ-
ation between cigarette smoking and MS warrants further investiga-
tion with well-designed prospective studies. Animal models and
basic research as well as ongoing large cohort studies will advance
our understanding of mechanisms. This is important because under-
standing the role of smoking in the MS pathogenesis may enable us
on one hand to temper disease onset and perhaps also control the
clinical course in high risk individuals by putting a brake on exposure.
On the other hand it may provide fruitful insight for understanding
MS pathogenesis and further development of therapeutical targets.
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